Sawai Focuses On New Products, Supply To 'Retain Trust' of Japan Generic Industry
New Company, Generic Strategy, Upsher-Smith Restructuring
Looking back at recent company decisions to shift product strategy, restructure its US Upsher-Smith business and acquire manufacturing sites from a former domestic competitor, Sawai's president shares the breadth of the Japanese firm’s vision.
You may also be interested in...
Kenzo Sawai, president of Japanese generics giant Sawai Pharmaceutical, tells Scrip in the first of a two-part exclusive interview about the firm’s strategy and backstory of efforts to maintain product supplies amid the country’s ongoing generic crisis. He also urges Japan to take "the best and only chance" to reform its drug pricing system to help the entire market survive.
Chugai has seen its attack on Sawai and Nichi-Iko over their generic eldecalcitol rivals to the originator’s Edirol brand dismissed by a Tokyo district court.
A major overhaul is in progress for Sawai’s Upsher-Smith business, after the Japanese parent company announced leadership changes and a “drastic restructuring” of the US unit in the wake of a significant impairment charge and a hefty annual operating loss that dragged down Sawai’s overall results.